To address the questions of whether Δ 9 -tetrahydrocannabivarin (THCV) can (a) enhance activation of 5-HT 1A receptors in vitro and (b) induce any apparent 5-HT 1A receptor-mediated anti-psychotic effects in vivo.
Introduction
In 2005, Russo et al. (2005) showed that one of the main components of Cannabis sativa, cannabidiol (CBD), in the micromolar range, binds to and functionally activates serotoninergic 5-HT 1A receptors. More recently we have reported that, at concentrations in the nanomolar range, CBD as well as its immediate precursor cannabidiolic acid (CBDA) can enhance the ability of the selective 5-HT 1A receptor agonist, 8-hydroxy-2-(di-npropylamino)tetralin (8-OH-DPAT), to stimulate [
35 S]GTPγS binding to rat brainstem membranes (Rock et al., 2012; Bolognini et al., 2013) . Cannabigerol, another phytocannabinoid, has been reported by our group to behave as a potent apparent competitive antagonist of the 5-HT 1A receptor (Cascio et al., 2010; Rock et al., 2011) .
The research described in this paper focused on the phytocannabinoid, Δ 9 -tetrahydrocannabivarin (THCV) (Figure 1 ), a propyl-analogue of Δ 9 -tetrahydrocannabinol (THC), and on the 5-HT 1A receptor. So far, it has been shown that this constituent of
Cannabis can behave in both in vitro and in vivo experiments as a CB 1 receptor antagonist Pertwee et al., 2007; Dennis et al., 2008; Ma et al., 2008) , and a CB 2 receptor partial agonist (Bolognini et al., 2010) . In addition, THCV has been reported to activate or block certain transient receptor potential (TRP) cation channels and to target GPR55 receptors De Petrocellis et al., 2011; . However, the ability of THCV to interact with 5-HT 1A receptors has not yet been investigated.
Here, for the first time, we present evidence that THCV (a) shares the ability of CBD to enhance 8-OH-DPAT-induced activation of 5-HT 1A receptors in vitro in pharmacological assays performed with membranes obtained from rat brainstem or from CHO cells stably transfected with the human 5-HT 1A and (b) produces, in rat models of schizophrenia-like symptoms, apparent anti-psychotic effects that are, at least in part, 5-HT 1A receptor-mediated.
Methods

Receptor nomenclature
The nomenclature of all the receptors mentioned in this paper conforms to BJP's Concise
Guide to Pharmacology, Alexander et al., 2013 .
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Animals
For in vitro experiments, brainstem tissues were obtained from 6 adult male Sprague Dawley rats maintained on a 12/12 h light/dark cycle with free access to food and water. These animals were purchased from Harlan UK Ltd (Blackthorn, UK). Before the removal of the brainstem, rats were killed by exposure to CO 2 followed by cervical dislocation. All animal care and experimental procedures complied with the UK Animals (Scientific Procedures) Act, 1986 and associated guidelines for the use of experimental animals. For in vivo experiments, male Sprague-Dawley rats (280-300g at the time of arrival) were purchased from Charles River (Calco, Italy) and randomly housed in groups of 4, on a 12/12 h light-dark cycle (lights on 08:00h) and in a temperature (24 ± 2°C) and humidity controlled environment (50 ± 10%), with a plastic tube for environmental enrichment. All animals had free access to food and water. We used a total of 204 rats that were randomly allocated to the experimental groups as follows: 18 control and 84 treated animals (6 rats for each experimental group) were tested for acute PCP experiments and 18 control and 84 treated animals (6 rats for each experimental group) were submitted to sub-chronic PCP experiments. 
In vitro procedures
CHO cells
Chinese hamster ovary cells stably transfected with cDNA encoding human serotoninergic 5-HT 1A receptors (a generous gift from Dr Keith Parker) were maintained at 37°C and 5% CO 2 in Dulbecco's modified Eagle's medium nutrient mixture F-12 HAM supplemented with 2
Accepted Article mM L-glutamine, 10% foetal bovine serum, 0.6% penicillin streptomycin and G418 (600 mg·mL-1).
Radioligand displacement assay
Membranes from Sprague Dawley rat brainstem were prepared as described by Bolognini et al. (2013) (Cascio et al., 2010) . Membranes from rat brainstem were pre-incubated for 30 min at 30ºC with 0.5 U ml -1 adenosine deaminase (200 U ml -1 ) to remove any endogenous adenosine. Non-specific binding was measured in the presence of 30 µM GTPγS. Assays were performed at 30ºC for 60 min (Cascio et al., 2010) . 
Dissociation Kinetics
Acute PCP administration
Acute inhibition of the NMDA receptor induces positive-like symptoms of schizophrenia in rodents, such as hyperlocomotion and stereotypies, and this is a model often used to predict the effect of substances with potential antipsychotic properties (Bubenikova-Valesova et al., 2008a; Large, 2007) .
At post-natal day 75, the effects of drug treatments on the stereotyped behaviour and increases in locomotor activity induced by acute PCP administration (5 mg kg -1 i.p.) were assessed according to the treatment schedule shown in 'Results'.
Sub-chronic PCP schedule
A sub-chronic treatment regime with PCP followed by a washout period, with animals tested in the drug-free state, gives lasting cognitive deficits and negative-like signs with reasonable similarity to the neuropathological and behavioural disturbances of the disorder and is currently considered a useful model for testing the efficacy of novel antipsychotics against affective components and cognitive impairments of psychotic disorders (Neill et al., 2010 (Neill et al., , 2014 . Animals were treated with either saline or PCP once a day for 7 days, according to a slightly modified version of the treatment schedule described by Seillier et al. (2010) and
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shown in 'Results'. After 7 days of withdrawal, rats were tested in the novel object recognition (NOR) test, social interaction test and forced swim test (FST).
Behavioural tests
Spontaneous Locomotor Activity
Rats were placed in a computer-controlled infra-red activity monitor arena. The arena consisted of a clear acrylic box, 43×43×32 cm (Ugo Basile, Varese, Italy) placed in a soundattenuating room. The cage was fitted with two parallel infrared beams, located 2 and 6 cm from the floor and cumulative horizontal and vertical movement counts were recorded for 50 min. During this period, stereotyped behaviours were scored by two observers blind to the treatment groups according to the rating scale described by Sams-Dodd (1998) . Horizontal locomotor activity and stereotypies were calculated in 10-min blocks. The total scores of the whole 50 min test session (i.e. the sum of the scores recorded for each 10 min block) were calculated and converted to area under the curve (AUC) values using GraphPad Prism 5.0 software.
Novel Object Recognition Test (Classic and Spatial)
The experimental apparatus used for the object recognition test was an open-field box (43 x 43 x 32 cm) made of Plexiglas, placed in a dimly illuminated room. Animals performed each test individually. The experiment was performed and analyzed as previously described by Zamberletti et al. (2012) . Briefly, each animal was placed in the arena and allowed to explore two identical previously unseen objects for 5 min (familiarization phase). After an inter-trial interval of 3 min one of the two familiar objects was replaced by a novel, previously unseen object and rats were returned to the arena for the 5-min test phase. During the test phase the time spent exploring the familiar object (Ef) and the new object (En) was videotaped and recorded separately by two observers blind to the treatment groups and the discrimination index was calculated as follows: [(En-Ef)/(En+Ef)] x 100.
Social Interaction Test
This test was carried out in a room illuminated with a dim overhead light. On the day of testing, each animal was habituated for 10 min in the test arena (60 x 60 x 60 cm), an openfield box made of Plexiglas. During the test session, each animal was allowed to explore freely an unfamiliar congener in the arena for 10 min. The arena was cleaned with 0.1% acetic acid and dried after each trial. Social behaviors were defined as sniffing, following, grooming, mounting and nosing. Aggressive behaviours were defined as attacking, biting, tail
Accepted Article rattling and aggressive grooming. The whole testing phase was videotaped, analyzed by two observers blind to the treatment groups; we also recorded the time spent in social behaviors and the number of aggressive behaviors.
Forced Swim Test
Animals were tested in a modified version of the FST that included only a single session of swimming Zamberletti et al., 2012) , since our objective was to measure any changes in a pre-existing behavioral deficit induced by PCP. Briefly, rats were forced to swim for 15 min inside a clear 50 cm tall, 20 cm diameter glass cylinder filled to 30 cm with 25°C water. The session was videotaped for later analysis of the following parameters:
immobility (time spent by the animal floating in the water making only those movements necessary to keep its head above the water), swimming (active swimming movements to the centre of the cylinder), and climbing (forceful thrashing movements with forelimbs against the walls of the cylinder). The time spent in each of these behaviors was measured by an experimenter blind to the treatment groups.
In Vivo Data Analysis
Behavioural data were expressed as mean values ± SEM of 6 animals per group and analysed by three-way ANOVA with PCP, THCV and WAY100635 as independent variables, or by two-way ANOVA with PCP and THCV/CLZ/AM251 as independent variables followed by Bonferroni's post hoc test to examine group differences. The level of statistical significance was set at P < 0.05.
Results
In vitro experiments
First, we investigated whether THCV shares the ability of CBD to enhance the activation of 5-HT 1A receptors in rat brainstem membranes. Interestingly, we found that, unlike CBD, THCV (100 nM) induced a statistically significant increase (240.9-fold) in the potency (EC 50 ), but not in the efficacy (E max ), with which 8-OH-DPAT stimulates [ 35 S]GTPγS binding to these membranes ( Figure 2A and Table 2 ). When tested alone, THCV
(1 nM to 10 µM) did not affect [ Furthermore, we found that in these membranes, THCV potently, but only partially, displaced 8-[ 3 H]-OH-DPAT from specific binding sites ( Figure 2C and Table 1 ).
Next, we performed experiments with membranes obtained from human 5-HT 1A -transfected CHO cells that, in contrast to brain tissue, do not express other types of receptor.
Accepted Article
We found that, in these membranes, THCV (100 nM) induced a significant increase in the efficacy (E max ), but not in the potency (EC 50 ), with which 8-OH-DPAT activates human 5-HT 1A receptors ( Figure 2D and Table 2 ). When THCV was tested alone in the [
S]GTPγS
binding assay, it did not induce any detectable effect at 1 nM to 10 µM ( Figure 2E ). Also, in the same membranes, we found that THCV significantly increased the binding of 8-[ 3 H]-OH-DPAT to specific binding sites ( Figure 2F ), while the binding of this tritium-labelled compound was completely prevented by 8-OH-DPAT ( Figure 2F and Table 1 ).
Since there is evidence that the 5-HT 1A receptor possesses an allosteric binding site (Barrondo et al., 2009) , we also investigated the ability of the 8-OH-DPAT-potentiating concentration of THCV (100 nM) to alter the rate at which 8- Neither the time spent exploring the two identical objects during the familiarization phase nor locomotor activity were altered in any of the groups analyzed (data not shown). 
Effect of THCV administration on PCP-induced behavioural alterations
Effect of AM251 administration on PCP-induced behavioural alterations
Discussion
The results from our investigation clearly show that THCV possesses an ability to interact with serotoninergic 5-HT 1A receptors both in vitro and in vivo. Turning first to our in vitro data, these showed that THCV, at 100 nM, significantly increased the potency (EC 50 )
but not the efficacy (E max ), with which DPAT activates 5-HT 1A receptors in rat brainstem membranes, thus behaving as a potential positive allosteric modulator of the 5-HT 1A receptor.
Also, we found that, like 8-OH-DPAT, THCV potently displaced 8- receptors. However, in the same cells, we found that 100 nM THCV did not alter the rate of dissociation of 8-[ 3 H]-OH-DPAT from specific binding sites.
These in vitro results together with evidence already published that activation of 5-HT 1A receptors in vivo can ameliorate at least some signs of schizophrenia (Ohno, 2011;  Accepted Article Bantick et al., 2001; Shimizu et al., 2013) , prompted us to investigate whether THCV can produce any apparent antipsychotic effects in vivo, and if so, whether any of these effects are 5-HT 1A receptor-mediated. This we did in a pharmacological model of schizophrenia in which rats are treated acutely or pretreated sub-chronically with PCP. Thus, overall, we found first, that on single administration, THCV was as effective as the established atypical antipsychotic, CLZ, in reverting both positive-and negative-like signs of schizophrenia, and cognitive impairments, and second, that many of the effects of THCV that we observed in these in vivo experiments appeared to be mediated, at least in part by the 5-HT 1A receptor. In rats pretreated with vehicle instead of PCP, neither THCV nor CLZ produced any effect in any of the behavioural tests that we used.
Our in vivo experiments with THCV showed that it prevented hyperlocomotion and stereotypies induced by acute PCP administration, and that in the sub-chronic PCP model, it restored social behaviours and counteracted the increase in the time spent in immobility in the FST. Moreover, THCV administration was able to normalize cognitive performance in PCPpretreated rats. Importantly, the ability of THCV to reverse behavioural changes induced by acute PCP injections, such as stereotypies and hyperlocomotion, is suggestive of a beneficial effect on positive-like signs, whereas its efficacy in normalizing the behavioural alterations induced by sub-chronic PCP in the other tests, although not specific to schizophrenia, may predict THCV effectiveness for treating negative and cognitive symptoms of this disorder, such as memory impairment and deficits in social interaction.
We also found that pretreatment with the selective 5-HT 1A antagonist, WAY100635, prevented many of the apparent beneficial effects of THCV on PCP-induced behavioural alterations without affecting any of these effects of PCP in the absence of THCV. Thus, the ability of THCV to interact in vivo with these receptors might represent one of the molecular mechanisms responsible for its antipsychotic-like properties, in line with previous reports indicating that increasing the activation of 5-HT 1A receptors could be a promising strategy for antipsychotic therapy (Bantick et al., 2001; Meltzer et al., 2012; Newman-Tancredi, 2010) . It is noteworthy, however, that although WAY100635 completely blocked the reversal by THCV of PCP-evoked stereotypies, it did not reduce the ability of (Scorza et al., 2010) .
Furthermore, our findings that pretreatment with WAY100635 prevented THCV from producing any recovery from PCP-induced social withdrawal are in line with evidence obtained from other preclinical studies that 5-HT 1A agonism can improve PCP-induced social behaviour deficits in rodents (Snigdha and Neill, 2008; Depoortere et al., 2007; BubenikovaValesova et al., 2008b) , and with the concept that optimized stimulation of 5-HT 1A receptors is required to maximize treatment benefits with regard to some aspects of social abilities (Depoortere et al., 2007; Bruins Slot et al., 2005; Bubenikova-Valesova et al., 2008b) .
Despite the evidence that 5-HT 1A receptor agonists can produce apparent anti-depressant effects both in traditional and in modified versions of the FST (Lucki et al., 1994; Cryan et al., 1997; De Vry, 1995) , the ability of THCV to reverse PCP-induced immobility in the FST was not dependent upon its action at 5-HT 1A receptors, as pre-treatment with WAY10063 did not prevent THCV from producing this effect.
Finally, in the NOR test, WAY100635 by itself partially restored recognition memory in PCP-pretreated rats, possibly indicating that 5-HT 1A receptors may be involved in the impairment of recognition memory triggered by sub-chronic PCP administration in rats.
Since sub-chronic treatment with PCP has been reported to increase cortical 5-HT 1A receptor binding (Choi et al., 2009 ) and 5-HT release (Etou et al., 1998; Martin et al., 1998; Adams and Moghaddam, 2001; Amargós-Bosch et al., 2006) , it is possible that 5-HT 1A antagonism could counteract PCP-induced enhancement of serotonergic stimulation, thus resulting in the observed improvement of cognitive performance. However, the fact that the reversal by THCV of PCP-induced cognitive impairment in the NOR test was not completely prevented by WAY100635, suggests that other molecular mechanisms may have contributed to the ameliorating effect of THCV in this test.
One such mechanism may be antagonism of the cannabinoid CB 1 receptor by THCV.
Thus, at the dose used in the present study, THCV has been reported to produce such antagonism (Pertwee, 2008) and we hypothesize that this action could contribute to the observed recovery of recognition memory induced by THCV since CB 1 receptor antagonism has been extensively proven to have pro-cognitive effects (De Bruins et al., 2010; Black et al., 2011; Vaseghi et al., 2012; Guidali et al., 2011; Seillier et al., 2010) . In line with previously published data, here we demonstrated that the established CB 1 receptor antagonist, AM251, was effective in reversing the negative-like symptoms and cognitive impairment induced by Accepted Article sub-chronic PCP. Interestingly, unlike THCV, AM251 did not counteract acute PCP-evoked hyperlocomotion and stereotypies. This is in line with previous reports that after acute administration, CB 1 receptor antagonists fail to show any activity in models of positive symptoms of schizophrenia (Black et al., 2011; Martin et al., 2003; Thiemann et al., 2008) , suggesting that antagonism of the CB 1 receptor may not reduce such symptoms. In this context, its ability to enhance activation of 5-HT 1A receptors and block activation of CB 1 receptors simultaneously could make THCV particularly effective as a therapeutic agent for the treatment of schizophrenia, a possibility that merits further exploration, for example by investigating its efficacy in other animal models of schizophrenia.
It is well-established that drugs, like rimonabant, that are able to antagonize cannabinoid CB 1 receptors, may also show depressive-like effects, including suicidality (Beyer et al., 2010) . The mechanism(s) by which rimonabant shows these side effects are not yet known, one possibility being that at high doses rimonabant behaves as an inverse agonist, rather than as a 'neutral' antagonist at the CB 1 receptors (Pertwee et al., 2005) . On the contrary, THCV, at the dose used in this study (2 mg/kg) lacks of inverse effect, thus behaving as a CB 1 receptor 'neutral' antagonist (Pertwee, 2008) . The lack of inverse effect might make THCV a drug safer than rimonabant. Moreover, it has been reported that a major limitation in the use of neuroleptics is the risk of short-and long-term side effects, such as significant weight gain and alterations in glucose metabolism (Shams and Muller, 2014) . In contrast, THCV has been reported to exert anti-obesity effects in mouse models (Wargent et al., 2013) , suggesting that, unlike current antipsychotics, its administration would not produce unwanted increases in body weight.
In conclusion, this investigation has shown for the first time that THCV can affect the activation of 5-HT 1A receptors both in vitro and in vivo. Our in vitro results, obtained from experiments performed with both rat brainstem and human 5-HT 1A CHO cell membranes, strongly support the hypothesis that THCV might modulate the activation of these receptors indirectly, rather than by binding directly to their orthosteric sites. Our in vivo experiments with rats yielded data showing that, like the established anti-psychotic drug, CLZ, THCV can potently antagonize stereotyped behaviour, reduce the amount of time spent immobile in the forced swim test, and normalize hyperlocomotor activity, social behaviour and cognitive performance in PCP models of schizophrenia-like symptoms. The 5-HT 1A receptor antagonist, WAY100635, abolished the ability of THCV to modify PCP-induced stereotyped and social behaviour, but it had no effect in the FST and only partially reduced the suppressant effect of THCV on PCP-induced cognitive deficiency in the NOR test, thus suggesting that these Accepted Article apparent beneficial effects of THCV were not mediated only by 5-HT 1A receptors. We speculate that one additional action that may underlie these apparent beneficial effects, is the antagonism by THCV of the cannabinoid CB 1 receptor. 
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